Favorable outcome of retreatment by direct‐acting antivirals for hepatitis C patients with daclatasvir plus asunaprevir combination therapy failure

Tojima, Hiroki; Kakizaki, Satoru; Takakusagi, Satoshi; Hoshino, Takashi; Naganuma, Atsushi; Nagashima, Tamon; Namikawa, Masashi; Ueno, Takashi; Shimada, Yasushi; Hatanaka, Takeshi; Takizawa, Daichi; Arai, Hajime; Sato, Ken; Takagi, Hitoshi; Uraoka, Toshio

doi:10.1111/hepr.13462

Cited by 5 publications

(4 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One RCT in HBV patients reported that adefovir after hepatectomy reduced the risk of late recurrence after two years of treatment and prolonged survival [ 30 ]. As for the HCV, SVR can now be achieved with a high rate with only a few side effects with the advent of DAA therapy [ 10 – 13 ]. Several observational studies have reported that HCV treatment generally reduces or improves liver function deterioration [ 31 , 32 ] and contributes to the improvement of overall survival by reducing the risk of non-liver diseases such as cardiovascular disease and neurological diseases [ 33 – 35 ].…”

Section: Discussionmentioning

confidence: 99%

“…For HBV, nucleoside/nucleotide analogs (NA) can be used to control virus replication [ 5 – 9 ]. For hepatitis C, direct-acting antivirals (DAAs) have recently made it possible to achieve a high rate of sustained viral response (SVR) [ 10 – 13 ], both of which could improve the prognosis of patients with chronic viral liver disease [ 14 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The impact of background liver disease on the long-term prognosis of very-early-stage HCC after ablation therapy

et al. 2022

View full text Add to dashboard Cite

Background and aim The long-term prognosis of hepatocellular carcinoma (HCC) treated at a very-early-stage (the Barcelona Clinical Liver Cancer (BCLC) classification stage 0) was unclear, especially in terms of background liver disease. Methods This single-center, retrospective study included 302 patients with BCLC stage 0 HCC treated with radiofrequency ablation (RFA) and followed for at least six months. We examined the impact of background liver disease on overall survival and recurrence. Results The median age was 72 (range; 36–91) years; the median tumor diameter was 15 (range; 8–20) mm. The etiologies of background liver disease were hepatitis B virus infection (HBV) in 24 cases, hepatitis C virus infection (HCV) in 195 cases, and non-viral (NBNC) in 83 cases. Among the patients with HCV, 63 had achieved sustained virological response (SVR) by antiviral therapy (HCV SVR) before developing HCC (n = 37) or after HCC treatment (n = 26), and 132 had active HCV infection (HCV non-SVR). The median overall survival was 85 (95% CI; 72–98) months, and the median recurrence-free survival was 26 (95% CI; 20–30) months. Active infection with hepatitis C virus negatively contributed to overall survival (HR 2.91, 95% CI 1.31–3.60, p = 0.003) and recurrence-free survival (HR 1.47, 95% CI 1.06–2.05, p = 0.011). Conclusions The prognosis of RFA treatment for very early-stage HCC was favorable. Achieving SVR in hepatitis C was important for further prognosis improvement.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

The impact of background liver disease on the long-term prognosis of very-early-stage HCC after ablation therapy

et al. 2022

View full text Add to dashboard Cite

show abstract

“…We also reported that patients who failed to achieve an SVR with DCV+ASV were able to achieve an SVR at a high rate with additional DAA treatments (23). DCV+ASV has been available for over five years now, which has allowed for the long-term observation of treated cases; however, reports with appropriate follow-up are still lacking.…”

Section: Introductionmentioning

confidence: 97%

Follow-up after Direct-acting Antiviral Treatment for Chronic Hepatitis C Virus Infection: Most Patients Are Followed Appropriately

Tojima

Kakizaki

Takakusagi³

et al. 2021

Intern. Med.

Self Cite

View full text Add to dashboard Cite

Objective Chronic hepatitis C virus (HCV) infection carries a residual risk of hepatocarcinogenesis even after viral elimination, so appropriate follow-up is necessary. The present study investigated the current hospital visits and hepatocarcinogenesis status of patients who received daclatasvir plus asunaprevir treatment (DCV+ ASV) to determine whether or not appropriate follow-up was being performed. Methods We retrospectively analyzed hepatocarcinogenesis, the overall survival, and the length of hospital visits in 442 patients who applied for the medical expense subsidy system for viral hepatitis and received DCV+ASV treatment in Gunma Prefecture between October 2014 and December 2015. This also included 61 patients who had a history of hepatocellular carcinoma (HCC). Results Among 442 patients, 388 achieved a sustained viral response (SVR) by DCV+ASV therapy (87.8%), and 95.9% achieved an SVR if additional treatment was included. HCC was found in 75 cases (17.0%). A history of HCC, the FIB-4 index and the treatment effect SVR were determined to be factors affecting the incidence of HCC. Regarding the follow-up rate, 89.9% of patients continued to regularly visit the hospital after 5 years of treatment. However, patients ! 60 years old had significantly lower persistence rates than older patients. The persistence rate of hospital visits to the same institution was 67.7% over a 5-year period, which was significantly better in small and medium-sized institutions than in large, specialized institutions (71.7% vs. 63.9%, p=0.039). Conclusion Patients with direct-acting antiviral treatment generally received adequate follow-up, but younger patients had a slightly higher rate of follow-up interruption and were considered to need support.

show abstract

“…However, these therapies often have unsatisfactory levels of efficacy, and chronic hepatitis C has been recognized to be a refractory disease (Feld and Hoofnagle, 2005;Pawlotsky, 2006;Feld and Ward, 2021). Recently, novel anti-HCV therapies with direct-acting antivirals have been established, and the number of patients who respond to treatment has increased (Pawlotsky, 2013;Feld, 2014;Welzel and Zeuzem, 2014;Tojima et al, 2020;Bhattacharjee et al, 2021;Stanciu et al, 2021). Therefore, chronic hepatitis C is now considered to be a curable disease, and it has been recommended to proceed with the detection of untreated or undiagnosed individuals with chronic HCV infection.…”

Section: Introductionmentioning

confidence: 99%

Performance Evaluation of In Vitro Screening and Diagnostic Kits for Hepatitis C Virus Infection

Murayama

Momose

Yamada

et al. 2022

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

AimA reliable kit with high sensitivity and specificity is indispensable for diagnosing hepatitis C virus (HCV) infection. Detection kits for anti-HCV antibodies (anti-HCV) are used for screening, and quantification kits for HCV RNA and HCV antigen (Ag) are used for the definite diagnosis of HCV infection or the evaluation of the pathological condition of and therapeutic effects in patients with chronic hepatitis C. Several kits are currently available for these purposes and are provided for clinical use in Japan. In this study, we aimed to evaluate the performance of these kits.MethodsWe used International Standards for HCV RNA and HCV Ag and a regional reference panel to evaluate the performance of thirteen anti-HCV, five HCV RNA, and two HCV Ag kits.ResultsAll specimens in the regional reference panel were diagnosed correctly by all anti-HCV kits, although the distributions of the quantified values varied, and the ratios of titer classification were not identical across kits. All HCV RNA kits quantified the International Standard with minimum deviation and diagnosed the specimens of the reference panel correctly. The quantified values of the International Standard by two HCV Ag kits were inconsistent. HCV Ag titers of some specimens were underestimated owing to the amino acid polymorphisms in comparison with HCV RNA titers.ConclusionsThe evaluation with International Standards and the regional reference panel was useful for assessing the quality of screening and diagnostic kits for HCV infection, and such quality control is essential for the clinical usage of these kits.

show abstract

Favorable outcome of retreatment by direct‐acting antivirals for hepatitis C patients with daclatasvir plus asunaprevir combination therapy failure

Cited by 5 publications

References 33 publications

The impact of background liver disease on the long-term prognosis of very-early-stage HCC after ablation therapy

The impact of background liver disease on the long-term prognosis of very-early-stage HCC after ablation therapy

Follow-up after Direct-acting Antiviral Treatment for Chronic Hepatitis C Virus Infection: Most Patients Are Followed Appropriately

Performance Evaluation of In Vitro Screening and Diagnostic Kits for Hepatitis C Virus Infection

Contact Info

Product

Resources

About